
BioSenic halts ALLOB development
ALLOB was developed before the US$40.8m majority buyout of Bone Therapeutics by French Medsenic SAS last October. Before the reverse merger, in...

Sygnature Discovery Ltd acquires leading Canadian CRO
The purchase of NuChem Sciences for an undisclosed sum is the third in a series of acquisitions in sixteen months as part of Sygnature's global...

Bacterial-fungal consortium denitrifies wastewater by 100%
Researchers from China and Germany have developed a new biotechnological approach to clean up waste water from anorganic nitrite and nitrate more...

Researchers stop brain cell death in Alzheimer’s mice
The research team led by Prof. Bart De Strooper (VIB-KU Leuven/UK Dementia Research Institute), and Dr Sriram Balusu (VIB-KU Leuven) has finally...

Resistance blocker of immune checkpoint inhibitors gets patented
DT-9081, Domain Therapeutics’ selective EP4 receptor antagonist, preclinically synergised with PD1-checkpoint blockers and shrinked tumours by...

Smarter, faster, cheaper: Veeva shows how
Achieving the highest possible speed in innovation to meet patients’ unmet needs. That was the palpable goal all the pharmaceutical and life sciences...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...